SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing intense volatility and bearish sentiment as the community debates the sustainability of its debt-fueled Bitcoin acquisition strategy amid a prolonged market downturn. Investors are sharply divided, with many expressing concern over potential liquidity risks and dividend obligations while others view the current price action as a generational buying opportunity.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense volatility and heavy selling pressure as investors grapple with a structural decline, a surprise CFO transition, and deep uncertainty heading into earnings. The community remains sharply divided, with some betting on a generational value play backed by iconic brand status, while others fear a continued downtrap driven by persistent competition and weak guidance.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the market anticipates key catalysts, including the upcoming release of five-year open-label extension data for its Duchenne muscular dystrophy candidate and a pivotal court hearing regarding its commercial distribution rights. The community is actively discussing the potential for a broad label expansion and the strategic path toward independent commercialization as they monitor legal developments and progress toward an August PDUFA date.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a negative CHMP opinion for narsoplimab, though the community is actively debating the significance of strong institutional inflow and potential short covering following the dip. Shareholders are closely watching for management's next steps and potential appeal strategies, as many maintain that current market sentiment ignores the underlying value of the company's US operations and pipeline.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending as investors bet on a potential short squeeze, fueled by high short interest and aggressive company-led share buybacks. The community is actively debating the stock's fundamental turnaround and the impact of the newly appointed COO, with many traders drawing parallels to other high-profile squeeze plays.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors digest the launch of its proprietary prediction markets exchange, DKeX, while debating its potential to capture market share versus the risk of increased competition and regulatory scrutiny. Community sentiment remains polarized, with many users frustrated by the stock's recent volatility and performance relative to the broader market, even as bulls point to record-breaking engagement during the ongoing World Cup as a sign of long-term growth.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as massive institutional demand for AI memory drives intense trading activity and price target upgrades, despite ongoing volatility from broader tech sector sell-offs and concerns over rising consumer hardware costs. The community is heavily polarized, with many retail traders actively hunting for dips while bears highlight potential cyclical risks and institutional market manipulation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors debate the impact of a controversial new sponsorship deal with the Golden State Warriors while waiting for a material hyperscaler contract. Sentiment is sharply divided between those calling for a management change due to perceived lack of urgency and long-term bulls who continue to accumulate shares based on the company's extensive power pipeline and AI infrastructure potential.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as it aggressively scales its Indium Phosphide (InP) production to address the supply-demand bottleneck created by the hyperscale AI and co-packaged optics infrastructure boom. Community discussion remains polarized, with bulls pointing to the company's critical role in the AI hardware supply chain and production expansion, while bears highlight significant geopolitical risks, persistent cash burn, and volatile price action driven by heavy insider selling.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the upcoming fourth-quarter BLA submission for its prostate cancer therapy, aglatimagene besadenovec, and the recent appointment of Mark Sims as Chief Commercial Officer to lead launch readiness. The community is actively discussing the stock's potential as a platform play in immuno-oncology, highlighting clinical progress in lung cancer trials and strategic interest in its combination therapy approach with existing checkpoint inhibitors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic to Participate in Investor, Industry and Scientific Conferences in June Immunic to Participate in Investor, Industry and Scientific Conferences in June PR Newswire NEW YORK, June 10, 2026 NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology company...

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026...

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials...

Immunic Names Erik Lundgren Chief Executive Officer

(RTTNews) - Immunic, Inc. (IMUX), a late-stage biotechnology company, on Wednesday said it has appointed Erik Lundgren as its new chief executive officer, effective May 22, 2026, with employment set to begin on June 1...

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer PR Newswire NEW YORK, May 27, 2026 Proven Leader with Deep Multiple Sclerosis Expertise; Played Key...

EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO

Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates Immunic's Phase 3 trials in 2026.read more...

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout...

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the...

Immunic (NASDAQ:IMUX) Upgraded by Lifesci Capital to "Strong-Buy" Rating

Lifesci Capital raised shares of Immunic to a "strong-buy" rating in a report on Monday...

HC Wainwright Estimates Immunic's Q1 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Immunic in a report issued on Thursday, April 30th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.20) per share for t...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.

Immunic Inc

IMUX Stock Jumps 6% Pre-Market Today – Here’s The Latest Update On Its Compliance With Nasdaq Listing Rules 

Equity

Bearish Sentiment

$UBER only

$INTC only

Both $UBER and $INTC

Neither

Nancy Pelosi recently disclosed trades in both Uber ($UBER) and Intel ($INTC) - are you following her into either? Cast your vote below.

Are you following Nancy Pelosi into her latest trades - Uber ($UBER) and Intel ($INTC)?

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMUXImmunic Inc

Fundamentals

Latest IMUX News